<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03544606</url>
  </required_header>
  <id_info>
    <org_study_id>ISMN and labor induction</org_study_id>
    <nct_id>NCT03544606</nct_id>
  </id_info>
  <brief_title>Nitric Oxide Donor Isosorbide Mono Nitrate for Cervical Ripening in Induction of Labor</brief_title>
  <official_title>Nitric Oxide Donor Isosorbide Mono Nitrate for Cervical Ripening in Induction of Labor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ahmed nagy shaker ramadan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to evaluate and assess the effectiveness and safety of vaginal administration&#xD;
      of isosorbide mono nitrate (ISMN) to induce cervical ripening and shorten the interval time&#xD;
      between induction and delivery in women undergoing induction of labor.&#xD;
&#xD;
      Research Hypothesis:&#xD;
&#xD;
      In women undergoing induction of labor, vaginal administration of isosorbide mono nitrate&#xD;
      (IMN) is effective to induce cervical ripening and shorten the interval time between&#xD;
      induction and delivery.&#xD;
&#xD;
      .&#xD;
&#xD;
      Research Questions:&#xD;
&#xD;
      Does vaginal administration of isosorbide mono nitrate (IMN) induce cervical ripening and&#xD;
      shorten the interval time between induction and delivery in women undergoing induction of&#xD;
      labor?&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patient and methods&#xD;
&#xD;
      Type of study:&#xD;
&#xD;
      Prospective double blinded randomized placebo-controlled clinical trial.&#xD;
&#xD;
      Study setting:&#xD;
&#xD;
      The study will be conducted at Cairo university in labor ward of Kasr El Ainy Hospital.&#xD;
&#xD;
      Study period:&#xD;
&#xD;
      approximately 6 months from June 2018 to December 2018.&#xD;
&#xD;
      Study population:&#xD;
&#xD;
      Patients will be recruited in this study those attending labor ward at kasr el ainy hospital&#xD;
      for induction of labor after 39 weeks of gestation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 1, 2018</start_date>
  <completion_date type="Actual">October 15, 2020</completion_date>
  <primary_completion_date type="Actual">August 30, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The patients will be divided into 2 groups Group 1: 70 women: patients were induced by Intra vaginal isosorbide mono nitrate (Effox 40 mg MINAPHARM) Group 2: 70 patients induced by placebo (pyridoxine) administered in the posterior vaginal fornix.</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>To insure that everyone has the chance of participation, Randomization will be done using computer generated randomization sheet using statsdirect version 3. Double blinding will be done by one of the supervisors who will be the only one to know the key, thus the care provider and the patient will not know is it the drug or the placebo.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>admission-delivery interval</measure>
    <time_frame>up to 24 hours</time_frame>
    <description>The time from initiation of cervical ripening till delivery of placenta</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">140</enrollment>
  <condition>Induction of Labor Affected Fetus / Newborn</condition>
  <arm_group>
    <arm_group_label>isosorbide mononitrate group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>isosorbide mononitrate group (study group) 70 patients are induced by Intra vaginal isosorbide mono nitrate at 36, 24 , 12 before induction</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebos group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>70 patients induced by placebo (pyridoxine) placebo tablet of the same size and shape as the isosorbide mononitrate. administered in the posterior vaginal fornix at 36, 24 , 12 before induction</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>isosorbide mononitrate</intervention_name>
    <description>isosorbide mononitrate group (study group) 70 patients are induced by Intra vaginal isosorbide mono nitrate at 36, 24 , 12 before induction</description>
    <arm_group_label>isosorbide mononitrate group</arm_group_label>
    <other_name>Effox 40 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>70 patients induced by placebo (pyridoxine) administered in the posterior vaginal fornix.</description>
    <arm_group_label>placebos group</arm_group_label>
    <other_name>pyridoxine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Bishop score &lt; or = 6&#xD;
&#xD;
          -  Singleton pregnancy&#xD;
&#xD;
          -  39 or more completed weeks of gestation&#xD;
&#xD;
          -  Cephalic presentation&#xD;
&#xD;
          -  Average size of the fetus, and absence of pelvic contraction&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  any contraindication of labor induction listed in the American College of Obstetrics&#xD;
             and Gynecology&#xD;
&#xD;
               -  Previous classical or inverted T-shaped or unknown uterine incision&#xD;
&#xD;
               -  Previous hysterotomy/ myomectomy of the uterine corpus involving entry of the&#xD;
                  uterine cavity or extensive myometrial dissection&#xD;
&#xD;
               -  Previous uterine rupture&#xD;
&#xD;
               -  Placenta previa or Vasa previa&#xD;
&#xD;
               -  Abnormal fetal lie&#xD;
&#xD;
               -  Active genital herpes infection&#xD;
&#xD;
               -  Major degree of cephalopelvic disproportion and contracted pelvis&#xD;
&#xD;
               -  Grand multipara&#xD;
&#xD;
               -  Malpresentation&#xD;
&#xD;
               -  Over distension of uterus like polyhydramnios or multiple pregnancy&#xD;
&#xD;
               -  Invasive carcinoma cervix&#xD;
&#xD;
               -  Pregnancy following repair for vesicovaginal fistula&#xD;
&#xD;
               -  Prelabour rupture of membranes&#xD;
&#xD;
               -  Previous Lower segment cesarean section.&#xD;
&#xD;
               -  Umbilical cord prolapse.&#xD;
&#xD;
               -  Established fetal distress&#xD;
&#xD;
               -  Heart disease complicating Pregnancy&#xD;
&#xD;
               -  Liver disease complicating Pregnancy&#xD;
&#xD;
               -  Anemia complicating Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>waleed M el khyat, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>faculty of medicine - Cairo university</name>
      <address>
        <city>Cairo</city>
        <state>Kasr El Ainy</state>
        <zip>11562</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>May 18, 2018</study_first_submitted>
  <study_first_submitted_qc>May 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2018</study_first_posted>
  <last_update_submitted>November 13, 2020</last_update_submitted>
  <last_update_submitted_qc>November 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>ahmed nagy shaker ramadan</investigator_full_name>
    <investigator_title>director</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pyridoxine</mesh_term>
    <mesh_term>Isosorbide</mesh_term>
    <mesh_term>Isosorbide Dinitrate</mesh_term>
    <mesh_term>Isosorbide-5-mononitrate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

